Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 34

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 34
---
 Paul Clancy (the “Clancy Agreement”) pursuant to which Mr. Clancy began serving as the independent chairman of our board of directors, effective as of June 6, 2022. Under the Clancy Agreement, Mr. Clancy was entitled to receive an initial equity grant consisting of an option to purchase 119,772 shares of common stock, which vests over a four-year period in 16 equal quarterly installments following June 6, 2022, subject to Mr. Clancy’s continued service with us through each applicable vesting date. In addition, under the Clancy Agreement, Mr. Clancy was entitled to an annual cash retainer of $50,000, payable in quarterly installments. Consistent with the terms of the non-employee director compensation policy, following February 6, 2025, when the Clancy Agreement terminated in connection with our initial public offering, Mr. Clancy is entitled to an annual cash retainer of $70,000 for his role as chair of the board, and an additional $4,500 per year for his role as chair of the nominating and corporate governance committee, each payable in quarterly installments, as well as reimbursement for reasonable travel expenses incurred by Mr. Clancy for his attendance at meetings of our board of directors.

In March 2024, following our Series C financing, our board of directors granted Mr. Clancy a non-qualified stock option to purchase 65,713 shares of common stock, which vests in 48 equal monthly installments over a period of four years following March 4, 2024, subject to Mr. Clancy’s continued service with us through each applicable vesting date.

Laurie Stelzer

On November 12, 2024, we entered into a board of directors agreement with Laurie Stelzer (the “Stelzer Agreement”) pursuant to which Ms. Stelzer began serving as a director and chair of the audit committee, effective as of November 14, 2024. In accordance with the Stelzer Agreement, in November 2024, Ms. Stelzer was granted an initial equity grant consisting of an option to purchase 44,480 shares of common stock, which vests in equal annual installments over a three-year period following November 14, 2024, subject to Ms. Stelzer’s continued service with us through each applicable vesting date. In addition, Ms. Stelzer was entitled to an annual cash retainer of $